Member Info for CR1909

It's all in the RNS from 14th October.

· fund SNG001 manufacturing and device scale up activities, with the aim of producing c. 100,000 treatment courses per month in 2021;

What would change if an RNS came out weeks ago to say we could deliver 100k doses per month? Without a buyer or approval that in itself is meaningless. In what way would it give you any reassurance?

I disagree there.

Those sound like doubts because you want an update on manufacturing and doubts because we don't know a lot about P3 - the product hasn't changed. If anything the research into the role of interferons should give us more confidence in the success of SNG001.

Big - the fundamentals haven't changed. Any doubts you have today should have been the same doubt from months ago.

The SP isn't based on news which has been released, it's a market reaction.

I hoped it wouldn't come to this and we would have got news unexpectedly one day when at 180 or so to avoid this tension but unfortunately this is the position we are in.

I know some people are disappointed at the speed of the P3 trial. It could be that Synairgen themselves have deliberately prioritised Activ-2 and finishing the home trial.

Perhaps there is a bit more happening on P3 now because SNG are now turning a bit more attention to that with other things being in place.

I saw a link to this site a couple of weeks back and have been keeping an eye on it. I had no idea how many confirmed cases may be in the UK so it's interesting from a general awareness point of view.

The SA variant has started to steadily rise recently. I think that's the one to watch given its prevalence in France and that being our closest neighbour.

https://www.gov.uk/government/publications/covid-19-variants-genomically-confirmed-case-numbers/variants-distribution-of-cases-data

@theboyg

Go and do your homework and come back when you have a bit of knowledge.

Sorry, ignore that first question - it's 600 patients worldwide so that's for our global P3 and not an Activ-2 site.

Great finds gggg. Couple of quick questions:

The Texas link suggests 300 patients on SNG and 300 on Placebo. This is way above the 220 in total for P2 in Activ-2. Can we make any inferences on that?

That Belgian page also suggest s recruitment started somewhere in the EU on 13th Jan - do you think that's the UK start date or elsewhere in the EU?

Funnily enough HarChris, this is probably the most relaxed I have felt since investing in this share.

Previously, watching the price fall I would be edgy. Now though, even though this is my one and only investment,I feel very calm. The day to day SP now means little to me, until the point news next drops. Sooner rather than later would be preferable for news to arrive but I have absolute confidence in the Synairgen team that if results take longer than we anticipate, there will be good reason for it.

Aston - even if we have to wait until June, I don't think the SP will be significantly lower.

It could easily re-trace back into the 140's or so but there is a strong body of support who will be holding until news drops so can't see it going too much lower.

It may also depend on the Covid situation in June. By then we may all be back to eating out, visiting the shops and taking holidays in the UK - leading people to believe the pandemic is over. Or, we may be seeing the SA and Brazilian variants causing re-infection.

That's a long answer to say - I don't really know! :-)

Many years ago I used to work in the bookies. We had a couple of really big customers and we had to monitor their bets. All that really meant was the computer would keep a running total of how much they had gambled, lost and won.

Whe these guys won, they would hang about the shop, telling people about their winnings and giving them hot tips for the future. All the while behind the scenes we could see that over the course of a month or year, they had lost big sums of money.

Tiger - you are the online equivalent of these customers. You maybe haven't lost money but you like to lord up any profits to make out you're some expert trader. Perhaps starting a blog or small business is something yo should consider. Let people who want advice come to you and leave everyone else alone.

Well that's good to know!

I'll be even more grateful though if you can tell us when this will have a 1000% rise?

In my opinion this share currently sits in a bit of no-mans land which is why the SP is so volatile.

For your casual investor, they know nothing about Synairgen. They don't know about the science, the product,the name. There is nothing here that makes them want to put money in here and leave it.

For the big boys, it's not a risk they need to take. Polar obviously have but if you manage a fund then you can afford to watch from a distance, wait for the results to come out. For them it doesn't matter if they buy in at 350p when results are announced, rather than 100p a wee while back.

Day traders - kinda similar to your casual investor except willing to put some money in and take a quick profit.

All of this changes with successful results and sales though.

Anyway, why are we 3% down? Because just now we're still a small bio firm from Southampton. Could all change overnight though - which is why we are all here!

Thanks Matterhorn and agree Teamwork.

Price is something we get hung up on here. Either using it to base a valuation for the future share price or to rule SNG as too expensive for the mass market. All I was trying to say is that we're essentially guessing as none of us know the price.

Please correct me if I'm wrong, but....

My recollection is that SH was asked about cost and he made a comparison to the cost of Resmidivir but highlighted the data suggested SNG001 was far more effective, therefore we could easily charge a similar amount. Arguably you could charge more if it's a superior product.

Has it been confirmed anywhere what the cost might be? For all we know it could be cheap to make and there are negotiations to be had on cost.

I completely agree.

I know some point to this being a broad spectrum drug and the fact it was developed originally for COPD. All that is true but Covid is THE big opportunity to get to market and sell at huge scale.

If anything the other uses come off the back of approval for Covid in my opinion.

Well said Matt.

Of course the P3 was ambitious but it had to be if you want to be able to use a potentially lifesaving drug globally and at scale.

Although results may be slower than many of us would like, we have no idea what goes on behind the scenes. SH has spoken before about daily conversations with governments and big pharmas, plus we have manufacturing scaling up.

Please don't mistake no news for nothing happening.

I'm sure there is nobody as keen to get the data analyses and published as the Synairgen team themselves.

I know it's hard, and we all want to know asap, but just need to keep waiting a little longer.

Thanks all, I suppose it's better to stick to what we know is factual having been reported through official channels.

False news on the internet - who would have thought it?!